Registration of Rapid 1 Clinical Trial – First-ever Human Trial of a new AED product
RRR can advise the first in human clinical trial, known as the ‘RAPID 1’ trial, has received ethics approval and has been registered on the Australian New Zealand Clinical Trials Registry for participant recruitment. The trial will commence in the coming weeks.
For a description of the study design and primary study outcomes of the investigation, see the link here.
The Board has great pleasure in announcing that Mr James Orlando (Jim) has been appointed to the Board of Rapid Response Revival Research Limited as a Non-Executive Director and Chair of the Audit & Risk Committee.
Jim brings to the Board an extensive resume of accomplishments and expertise. He is currently a Non-Executive Director and Audit & Risk Committee Chair with Catapult Sports International Limited (ASX:CAT). Jim’s previous positions included CFO at AAPT Australia, CFO of PowerTel, the ASX listed Telecommunication service provider before it was sold to Telecom NZ in 2007 and CFO of Veda Group, leading its successful A$1.05 billion IPO, and subsequently managed the takeover offer in 2016 for A$2.6 billion.
On his appointment Jim outlined that he was personally excited about joining RRR, ‘For me, it was about the commitment RRR people have to delivering on a company vision that I care about. RRR is bringing something to the market (world) that will have a major positive impact and I wanted to be part of the effort. I also love the energy that people attracted to technology businesses bring to work every day and this is even more exciting when working on such an important product.’
Jim added that he sees his experience complementing the RRR team though his engagement, ‘… I gained a lot of confidence from the quality of the team Donovan has built, the actual delivery to commitment across all functional areas thus far, and perhaps most important, the focus the whole team has on developing a detailed plan to achieve the future vision. One area in particular is understanding business performance and ensuring that the company, as it grows, always has a focus on its key performance metrics starting with the customer.”
About Rapid Response Revival Research Limited
Rapid Response Revival is the innovators behind the CellAED® defibrillator technology – transforming everyday people into heroes.
The CellAED® is designed to assist everyday people and medical professionals to prevent many unnecessary deaths. It is a lightweight, affordable, and personal Automated External Defibrillator (AED) solution, targeting the current government and enterprise market as well as the personal and home AED market.
Rapid Response Revival Limited seeks to improve the survival rate of SCA by making fast treatment effective, simple and affordable – restarting hearts in cardiac arrest within the critical ‘Survival Gap’ (first 4 minutes) before emergency services arrive. This increases the survival rate of SCA victims who receive defibrillation within this ‘Survival Gap’ as high as 70% and helping to bridge the gap to professional care.